Back to Journals » Neuropsychiatric Disease and Treatment » Volume 16

Can Maternal Autoantibodies Play an Etiological Role in ASD Development?

Authors Dudova I, Horackova K, Hrdlicka M, Balastik M

Received 21 November 2019

Accepted for publication 10 April 2020

Published 3 June 2020 Volume 2020:16 Pages 1391—1398

DOI https://doi.org/10.2147/NDT.S239504

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Roger Pinder


Iva Dudova,1 Klara Horackova,2 Michal Hrdlicka,1 Martin Balastik3

1Department of Child Psychiatry, Charles University Second Faculty of Medicine, Prague, Czech Republic; 2Department of Psychiatry, Charles University First Faculty of Medicine, Prague, Czech Republic; 3Laboratory of Molecular Neurobiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic

Correspondence: Iva Dudova
Department of Child Psychiatry, Charles University Second Faculty of Medicine, University Hospital Motol, V Uvalu 84, Prague 15006, Czech Republic
Tel +420 224 433 458
Fax +420 224 433 420
Email iva.dudova@lfmotol.cuni.cz

Abstract: Autism spectrum disorder (ASD) is a heterogeneous condition with multiple etiologies and risk factors – both genetic and environmental. Recent data demonstrate that the immune system plays an important role in prenatal brain development. Deregulation of the immune system during embryonic development can lead to neurodevelopmental changes resulting in ASD. One of the potential etiologic factors in the development of ASD has been identified as the presence of maternal autoantibodies targeting fetal brain proteins. The type of ASD associated with the presence of maternal autoantibodies has been referred to as maternal antibodies related to ASD (MAR ASD). The link between maternal autoantibodies and ASD has been demonstrated in both clinical studies and animal models, but the exact mechanism of their action in the pathogenesis of ASD has not been clarified yet. Several protein targets of ASD-related maternal autoantibodies have been identified. Here, we discuss the role of microtubule-associated proteins of the collapsin response mediator protein (CRMP) family in neurodevelopment and ASD. CRMPs have been shown to integrate multiple signaling cascades regulating neuron growth, guidance or migration. Their targeting by maternal autoantibodies could change CRMP levels or distribution in the developing nervous system, leading to defects in axon growth/guidance, cortical migration, or dendritic projection, which could play an etiological role in ASD development. In addition, we discuss the future possibilities of MAR ASD treatment.

Keywords: maternal autoantibodies, autism spectrum disorder, animal models, CRMP2, therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]